Clinical trials using new cancer imaging and treatment technology start soon in N.S. - Action News
Home WebMail Tuesday, November 26, 2024, 07:10 AM | Calgary | -17.5°C | Regions Advertise Login | Our platform is in maintenance mode. Some URLs may not be available. |
Nova Scotia

Clinical trials using new cancer imaging and treatment technology start soon in N.S.

A new cancer treatment that combines artificial intelligence with radiation therapy to pinpoint cancers is a significant step forward, say officials in Nova Scotia.

Targeted therapy expected to reduce number of required radiation sessions, says medical expert

Two masked doctors stand beside a large medical machine.
Nova Scotia Health's chief of medical physics, Dr. James Robar, is shown alongside colleague Dr. Amanda Cherpak, associate professor and director of clinical medical physics, with the new Ethos therapy system at the QEII Hospital in Halifax. (Nova Scotia Health)

A new system for treatingcancerunveiled in Halifax on Monday will be better able to pinpoint tumours and focus radiation to avoid damaging healthytissue, doctors say.

Nova Scotia will bethe first place in Canada to use the equipment calledEthos, made byCalifornia-basedVarian Medical Systems. It'salready been installed at the QEII Hospital in Halifax where clinical trials are expected to begin within weeks.

Dr. James Robar, chief of medical physics for Nova Scotia Health, describes the technology as a potential game changer in cancer treatment at a Monday news conference.

It uses artificial intelligence combined with radiation therapy to target tumours with more precision.

He said he expectsthe therapy will result in shorter wait times and result infewer radiation treatments than cancerpatients typicallyendure now, such asa month of daily doses.

"Imagine a technology that could compress that month of treatments through improved precision and accuracy into one to five days, absolutely transformational," Robar said.

The system he said is not yet approved by Health Canada but the company said it already has clearance in the U.S.

Treatment avoids radiation of healthy tissues

Varian CEOChris Tothsaid the Ethossystem producesimages of tumours beforedeliveringradiation. In that way, it can track changes in the cancer and the rest of the body to zero in on tumours throughout treatment.

"You're not only eradicating the disease but you're improving quality of life and reducing toxicities," Toth said, adding it has not been possible with previous approaches. "The challenge has been that there is a lot of healthy tissue and critical structures that get toxicity and so patients live with a tremendous number of morbidities."

A large medical machine.
The system is designed to provide treatment within a 15 minute appointment. (Nova Scotia Health)

Varian is providing a significant in-kind contribution to the project, along with $12 million in operational funding from the Province of Nova Scotia, and $8 million in donations through the QEII Foundation, according to a news release.

'We're bringing it to the world'

Provincial Health Minister Michelle Thompson said the treatment could make a big difference for many Nova Scotians.

"One in two Nova Scotians will be touched by cancer and so for us to be able to have that cutting-edge therapy here, not waiting for the rest of the world to bring it to us, we're bringing it to the world," Thompson said.

Thirtypatients will be taking part in the first study using the technology.The focus of it will be on breast cancer, liver cancer and lung cancer. A follow up trial is being planned on head and neck cancer.

Robar said he expectsfull clearance from Health Canada in about a year.

"When it is Health Canada cleared we will hit the ground running," hesaid.

Add some good to your morning and evening.

Get the latest top stories from across Nova Scotia in your inbox every weekday.

...

The next issue of CBC Nova Scotia newsletter will soon be in your inbox.

Discover all CBC newsletters in theSubscription Centre.opens new window

This site is protected by reCAPTCHA and the Google Privacy Policy and Google Terms of Service apply.